Antimicrobial resistance
As bacteria that cause infection adapt to withstand antibiotics, the potential for antimicrobial resistance to cause a global health crisis looms large. Scientists and policymakers are working together to find ways to fight back against this threat.
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from Shionogi & Co., Ltd. in producing this Outlook. The sponsor retains sole responsibility for the following message.
Shionogi is a leading global research-driven pharmaceutical company established more than 140 years ago in Osaka, Japan. Shionogi maintains its headquarters in Osaka and has offices in Europe and the US and other countries. We have an experienced team of research and development experts who continue to build on our strong heritage of discovering and developing novel products to treat infectious diseases. We value our strong relationships with academia, innovative alliance partners, and other stakeholders.
Shionogi recognises the urgent need to address antimicrobial resistance (AMR) and is actively working to develop new products and make them available to those who need them, while maintaining a commitment to appropriate use and high environmental standards. We have discovered important antibiotics and antiviral medicines and have partnered with public institutions, academia, and other companies to address the COVID-19 pandemic.
Shionogi takes corporate social responsibility seriously. We are proud of our commitment to addressing infectious diseases, including those where AMR is an issue, and will take a leadership role in ensuring that new medicines are available to benefit both individual patients and society as a whole.
